High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial

« Previous Next »European Journal of Surgical Oncology
Volume 38, Issue 2 , Pages 110-117, February 2012

D.B.Y. Fontein
- Department of Surgical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333ZA Leiden, The Netherlands
- Corresponding author. Tel.: +31 71 526 3500; fax: +31 71 526 6744.
J.W.R. Nortier
- Department of Medical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333ZA Leiden, The Netherlands
G.J. Liefers
- Department of Surgical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333ZA Leiden, The Netherlands
H. Putter
- Department of Medical Statistics, Leiden University Medical Centre, Albinusdreef 2, 2333ZA Leiden, The Netherlands
E. Meershoek-Klein Kranenbarg
- Department of Surgical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333ZA Leiden, The Netherlands
J. van den Bosch
- Department of Medical Oncology, Albert Schweitzer Hospital, P.O. Box 444, 3300AK Dordrecht, The Netherlands
E. Maartense
- Department of Medical Oncology, Reinier de Graaf Hospital, P.O. Box 5011, 2600GA Delft, The Netherlands
E.J.Th. Rutgers
- Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands
C.J.H. van de Velde
- Department of Surgical Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333ZA Leiden, The Netherlands